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Abstract 
 
Candidate gene and genome-wide association studies (GWAS) have identified 15 independent genomic 
regions associated with bladder cancer risk. In search for additional susceptibility variants, we followed up 
on four promising single-nucleotide polymorphisms (SNPs) that had not achieved genome-wide significance 
in 6911 cases and 11 814 controls (rs6104690, rs4510656, rs5003154 and rs4907479, P < 1 × 10−6), using 
additional data from existing GWAS datasets and targeted genotyping for studies that did not have GWAS 
data. In a combined analysis, which included data on up to 15 058 cases and 286 270 controls, two SNPs 
achieved genome-wide statistical significance: rs6104690 in a gene desert at 20p12.2 (P = 2.19 × 10−11) 
and rs4907479 within the MCF2L gene at 13q34 (P = 3.3 × 10−10). ImputaƟon and fine-mapping analyses 
were performed in these two regions for a subset of 5551 bladder cancer cases and 10 242 controls. 
Analyses at the 13q34 region suggest a single signal marked by rs4907479. In contrast, we detected two 
signals in the 20p12.2 region—the first signal is marked by rs6104690, and the second signal is marked by 
two moderately correlated SNPs (r2 = 0.53), rs6108803 and the previously reported rs62185668. The 
second 20p12.2 signal is more strongly associated with the risk of muscle-invasive (T2-T4 stage) compared 
with non-muscle-invasive (Ta, T1 stage) bladder cancer (case–case P ≤ 0.02 for both rs62185668 and 
rs6108803). Functional analyses are needed to explore the biological mechanisms underlying these novel 
genetic associations with risk for bladder cancer. 
  
Introduction 
Each year ∼380 000 bladder cancer cases are diagnosed worldwide (1,2). While smoking is estimated to 
explain ∼50% of bladder cancer, genetic susceptibility has also been noted to contribute to its etiology (2–
4). Family history of bladder cancer in a first degree relative is associated with a ∼1.7-fold increased risk, 
comparable with many other common adult cancers (e.g. breast, prostate, colon) (5,6). To date, candidate 
gene and genome-wide association studies (GWAS) have identified 15 genomic regions that harbor bladder 
cancer genetic susceptibility variants. These include 1p13.3 (GSTM1), 2q37.1 (UGT1A cluster), 3q26.2 
(TERC), 3q28 (TP63), 4p16.3 (TMEM129 and TACC3-FGFR3), 5p15.33 (TERT-CLPTM1L), 8p22 (NAT2), 
8q24.21, 8q24.3 (PSCA), 11p15.5 (LSP1), 15q24 (CYP1A2), 18q12.3 (SLC14A1), 19q12 (CCNE1), 20p12.2 and 
22q13.1 (CBX6, APOBEC3A) (7–19). Based on analysis of the reported signals that reached a conclusive 
threshold of genome-wide significance (20), we estimate that many additional common genetic variants for 
bladder cancer are yet to be discovered (11). 
To identify new bladder cancer susceptibility variants, we followed up on four promising SNPs (P < 1 × 
10−6) that did not achieve genome-wide significance in our previously reported meta-analysis of three 
independently published GWAS performed in individuals of European ancestry [National Cancer Institute 
(NCI)-GWAS1, NCI-GWAS2 and the Texas Bladder Cancer Study (TXBCS)-GWAS] (11,12,19). In addition, we 
genotyped five promising SNPs identified in a genome-wide interaction study of smoking and bladder 
cancer risk (21). 
 
Results 
In our previous meta-analysis of three bladder cancer GWAS: NCI-GWAS1 (8,11), NCI-GWAS2 (19) and 
TXBCS-GWAS (12) totaling 6911 cases and 11 814 controls of European descent, we identified four SNPs 
with promising associations of P < 1 × 10−6 (19). These SNPs were genotyped in an independent set of 
samples (4427 cases and 5881 controls) with individual TaqMan assays. We also obtained genotype data 
from existing GWAS data for 1724 cases and 265 722 controls from Iceland and 1996 cases and 2853 
controls from the Netherlands (9,22) (see the Material and Methods section). Details of the studies and the 
genotyping data are summarized in Supplementary Material, Table S1. In a combined meta-analysis, two of 
the four promising SNPs achieved the threshold of genome-wide significance: rs4907479 at 13q34 (P = 3.3 × 
10−10) and rs6104690 at 20p12.2 (P = 2.19 × 10−11). Study-specific estimates are shown in Figure 1. Two 
other promising SNPs rs4510656 and rs5003154 did not achieve genome-wide significance with additional 
data (Supplementary Material, Fig. S1). 
We also evaluated five SNPs identified as suggestive in a genome-wide scan for interaction of smoking and 
bladder cancer risk (21). The most promising initial signals were rs1711973 (FOXF2) at 6p25.3 in never-
smokers (P = 5.18 × 10−7, OR = 1.34) and rs12216499 (RSPH3-TAGAP-EZR) at 6q25.3 in ever-smokers (P = 
6.35 × 10−7, OR = 0.75) (21). However, the current analysis in an addiƟonal set of almost 1000 never-
smokers and 3000 ever-smokers did not provide supportive evidence for association of these variants with 
bladder cancer risk (Supplementary Material, Table S2). 
To further refine the association signals with bladder cancer risk, we imputed the 13q34 and 20p12.2 
regions in a subset of 5551 bladder cancer cases and 10 242 controls from NCI-GWAS1 and NCI-GWAS2. 
Imputation was done within 1 Mb windows centered on the GWAS markers and using the 1000 Genomes 
reference panel (Phase 3 October 2014). For the 13q34 region, we analyzed 1370 imputed and 146 
genotyped markers (Supplementary Material, Table S3). Among the 1516 markers evaluated, we identified 
29 additional SNPs in high linkage disequilibrium (LD, r2 > 0.8) with rs4907479 and associated with bladder 
cancer risk (P < 2.0 × 10−4). These variants are located within a 24 Kb genomic region, in the first two 
introns of the MCF2L gene (Fig. 2). Fine-mapping analysis showed that these variants are highly correlated 
and analyses adjusting for the GWAS SNP (rs4907479) did not reveal an independent signal, thus pointing 
toward a single susceptibility locus marked by rs4907479 (P = 1.92 × 10−5, OR = 1.13). 
Since bladder cancer risk variants at 20p12.2 have previously been reported (18,19), we sought to confirm 
and clarify these previous associations and determine if additional signals were present. After analysis of 
2344 imputed and 246 genotyped markers across the 20p12.2 region, we observed three markers with 
comparably strong signals: rs6104690 (P = 3.97 × 10−5, OR = 1.11), rs6108803 (P = 1.82 × 10−6, OR = 1.18) 
and rs62185668 (P = 1.39 × 10−5, OR = 1.14, Table 1, Fig. 3 and Supplementary Material, Table S4). Per-
allele odds ratio (OR) estimates adjusting for the various 20p12.2 marker combinations are presented in 
Table 1. Regardless of the models, rs6104690 and rs6108803 showed significant associations with bladder 
cancer risk (P ≤ 0.03), while the association for rs62185668 was no longer significant (P = 0.25) when 
adjusting for the newly identified 20p12.2 SNP rs6108803. Logistic models that adjusted for the effects of 
two other markers showed significant residual associations for rs6104690 (P = 0.03, OR = 1.07) and 
rs6108803 (P = 0.03, OR = 1.12), but not rs62185668 (P = 0.70, OR = 1.02) (Table 1). We observed only a 
weak association (OR = 1.07, 1.02–1.13; P = 1.00 × 10−2, Fig. 3) with bladder cancer risk for the previously 
reported rs4813953 (18). Haplotype analysis at 20p12.2 showed the strongest associations with bladder 
cancer risk when at least two risk alleles were present (P ≤ 4.10 × 10−6). We observed the most significant 
association with bladder cancer risk for the combination of rs6104690 and rs6108803; a haplotype with risk 
alleles of both markers had an OR = 1.21, P = 2.00 × 10−7 (Supplementary Material, Table S5). Further 
analysis in the same set of samples showed that the presence of risk alleles of all three SNPs did not 
improve the association (OR = 1.20, P = 5.00 × 10−7) above what was seen in the two-SNP haplotype 
analysis (Supplementary Material, Table S6), implying that the bladder cancer association signal in the 
20p12.2 region could be efficiently captured by genotyping two markers, rs6104690 and rs6108803. 
Analysis by tumor stage and grade (Table 2 and Supplementary Material, Table S7) did not show significant 
associations with tumor characteristics for the 13q34 signal rs4907479. For the 20p12.2 SNPs rs6108803 
and rs62185668, the signal was stronger for muscle-invasive bladder cancer (MIBC, T2–T4 stages) 
compared with non-muscle-invasive bladder cancer (NMIBC, stages Ta and T1, case–case analysis, P ≤ 0.02 
for both markers), while there was no statistically significant difference for rs6104690. Case–case analysis 
adjusting for the 20p12.2 variants showed stronger association with MIBC for rs6108803 and rs62185668, 
which was not significantly affected by further adjustment for rs6104690 (Supplementary Material, Table 
S8). Association with tumor stage was consistent across studies (I2 = 0.0, P = 0.49 for rs6108803, 
Supplementary Material, Fig. S2). SNPs in the 20p12.2 region were not significantly associated with tumor 
grade (P > 0.56) or high/low risk of progression tumor classification (P > 0.52, low risk defined as Ta stage 
with G1/G2 grade; high risk as T1–T4 or G3/G4 grade). 
We analyzed the bladder cancer dataset containing data on 412 cases of The Cancer Genome Atlas (TCGA) 
(24), of which 391 had germline genetic data, to explore possible molecular phenotypes that might be 
related to the 13q34 and 20p12.2 signals. Since the SNPs of interest were not genotyped by TCGA, we used 
proxies for these variants based on European populations of the 1000 Genomes Project (Materials and 
Methods). We evaluated MCF2L mRNA expression in 375 bladder tumors in relation to rs2993291 (proxy 
for rs4907479, r2 = 0.96) but observed no significant association (Supplementary Material, Fig. S3). The 
three SNPs at 20p12.2 (rs6104690, rs62185668 and rs6108803) are located within a 33 Kb region in a 1.2 
Mb gene desert, at a distance of ∼335 and 880 Kb from the closest genes, JAG1 and BTBD3, respectively 
(Fig. 3). There are 6 proxy SNPs that are highly correlated (r2 > 0.8) with rs6104690; 30 proxy SNPs for 
rs62185668; while there are no proxies for rs6108803 (only 4 SNPs are in r2 > 0.6). For the TCGA analysis, 
we used rs6040291 as a proxy for rs6104690 (r2 = 1.0), rs6074214 as a proxy for rs62185668 (r2 = 0.97), 
while we could not perform analysis specifically for rs6108803 (the best proxy for rs6108803 in TCGA was 
rs6074214 with r2 = 0.45, this variant was already analyzed as a proxy for rs62185668). 
Expression of the closest genes, JAG1 and BTBD3, was not associated with genotypes of these SNPs in 381 
bladder tumors (Supplementary Material, Fig. S3A and B). Further, using TCGA bladder cancer data, we 
observed no evidence of associations for the proxy 13q34 and 20p12.2 markers with overall survival for 363 
patients and bladder cancer recurrence for 250 patients (data not shown). Analysis of TCGA data through 
the CBio Cancer Genomics Portal (25,26) showed that MCF2L was not commonly mutated in bladder 
cancer. Based on tumor data from 412 patients, somatic alterations in MCF2L were detected only in 16 
(4%) of all tumors, and gene amplifications represented most of these alterations (14 of 16 events). 
We performed in silico annotation using ENCODE (27) and HaploReg (28) databases, compiling information 
on histone modification marks in cell lines, transcription factor (TF) binding sites and DNase hypersensitivity 
sites (DHS). We noted from these data that the 13q34 region contains two regions with enrichment of 
multiple functional marks suggestive of regulatory functions close to SNPs in high LD with the GWAS SNP 
rs4907479. Importantly, these two functional regions also showed DHS in an urothelial cell line 
(Supplementary Material, Fig. S3). Future work will explore these regions for their possible role in 
regulating MCF2L or other genes. Similar analysis for the 20p12.2 region showed enrichment of multiple 
functional signals close to rs6104690 and several other areas but without strong specific patterns 
(Supplementary Material, Fig. S4). Since the SNP markers at 20p12.2 region associated with bladder cancer 
risk map to a gene desert area, more work is needed to explore possible functional effects of genetic 
variants associated with bladder cancer. 
The 20p12.2 and 13q34 regions also harbor markers associated with other phenotypes identified by 
published GWAS. SNP rs11842874 in the MCF2L gene at 13q34 was previously identified in a GWAS for 
osteoarthritis (29), but this variant was not associated with bladder cancer risk (P = 0.67, r2 = 0.01 and D′ = 
0.24 with rs4907479, Supplementary Material, Table S3). A 20p12.2 region SNP rs1327235, which was 
previously associated with blood pressure (23), showed a nominal association with bladder cancer risk in 
our set (OR = 1.09, P = 3.8 × 10−4, r2 = 0.25–0.41 with our best markers) (Fig. 3); there was no association 
for the bone density-associated SNPs rs3790160 and rs2273061 (30,31) (P > 0.10, r2 < 0.01 with our best 
markers). 
We have previously shown evidence for significant additive interactions with smoking for many bladder 
cancer susceptibility loci (15,19,32). There was a suggestion of an additive but not multiplicative interaction 
for the rs6108803 20p12.2 SNP and smoking (P-additive interaction = 0.04, P-multiplicative interaction = 
0.66). All other SNPs did not show any evidence of interaction (P ≥ 0.28) (data not shown). 
We also estimated the proportion of familial risk explained, based on all genetic variants identified to date 
that show association with bladder cancer at a genome-wide significant level. We estimate that all 
significantly associated SNPs identified so far explain ∼12% of familial risk for bladder cancer (33,34). 
 
 
Discussion 
Herein, we report a new bladder cancer susceptibility locus at 13q34 marked by rs4907479 (P = 6.4 × 
10−10) and refine the previously reported 20p12.2 region as a mulƟ-signal locus, with two associations, one 
marked by rs6104690 and a second marked by rs6108803 and rs62185668. Interestingly, the signal 
captured by rs6108803 and rs62185668 showed significantly stronger association with risk of MIBC 
compared with NMIBC, making this the first bladder GWAS signal to show a significantly stronger 
association with MIBC. 
Fine-mapping analysis of the 13q24 region showed that the signal detected for rs4907479 can be 
represented by at least 29 correlated variants (r2 ≥ 0.8), all located within the first two introns of the 
MCF2L gene. The association signal for rs4907479 was similar in groups stratified by tumor stage and grade. 
MCF2L is a guanine nucleotide exchange factor (GEF) for members of the RHO subfamily of the RAS 
superfamily (35). The N-terminally truncated protein isoform of MCF2L was initially identified as an 
osteosarcoma oncogene (36). In support of the possible role of this gene in bone disease, an MCF2L genetic 
variant rs11842874 has been strongly associated in GWAS for osteoarthritis in Europeans, but this variant 
was not associated with bladder cancer in our study. MCF2L was not found to be commonly mutated in 
bladder tumors studied in TCGA (25). The functional role of this GWAS signal is unclear since it was not 
associated with mRNA expression of MCF2L, overall survival or bladder cancer recurrence in TCGA bladder 
cancer dataset. ENCODE and HaploReg (27,28) in silico analysis suggest that this region may be important 
for regulation of genes in the region given enrichment of DHS; hence, future work is needed to explore the 
molecular phenotype of this genetic association and its role in bladder cancer risk. 
In follow-up analyses, we defined the 20p12.2 region as a multi-signal locus, which includes at least two 
signals, the first signal represented by our initial SNP rs6104690 (19) and now a second signal marked by a 
novel SNP rs6108803 and a previously reported rs62185668 (18). A combination of two markers, rs6104690 
and rs6108803 representing each of these 20p12.2 signals, most efficiently captured the bladder cancer 
association in this region in our combined dataset of NCI-GWAS1 and NCI-GWAS2. However, only the 
second signal, rs6108803/rs62185668 but not rs6104690, was associated with advanced tumor stage 
(MIBC). 
A previously identified SNP rs7257330 upstream of CCNE1 gene in 19q12 region showed an association 
with aggressive disease, which is based on a combination of tumor stage and grade information and 
corresponds to high risk of progression definition used here, but this was mostly driven by high grade (37). 
The 20p12.2 markers capture another important clinical difference, by tumor stage, an association with 
MIBC. However, our study and a previous study that analyzed rs62185668 (18) showed no difference in 
association for these markers by tumor grade or by low/high risk of cancer progression. MIBC represents up 
to 20% of all bladder cancer cases; this is a clinically severe cancer subtype that requires radical cystectomy 
and systemic chemotherapy. The risk of developing life-threatening metastatic disease remains high even 
after this treatment, resulting in relative 5-year survival rate of 15–63%, compared with 88–98% for NMIBC 
(http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-survival-rates). If validated in 
additional samples, associations at the 20p12.2 region might lead to a better understanding of genetic 
predisposition to MIBC. The associated 20p12.2 SNPs are located in a 1.2 Mb gene desert; expression of the 
closest genes JAG1 and BTBD3 was not associated with these variants in TCGA bladder cancer dataset, and 
alternative functional mechanisms will be explored. 
We were unable to confirm associations for five loci previously identified as suggestive in a genome-wide 
interaction study of smoking and bladder cancer risk (21). These results indicate that additional large 
sample sets will be needed to explore loci with differential effects by smoking status. 
In conclusion, we have identified a new susceptibility locus at 13q34 and refined our understanding of 
20p12.2 as a multi-signal locus associated with bladder cancer risk in Europeans. Based on fine-mapping, 
we have identified optimal variants associated with bladder cancer risk that can be pursued in future 
studies. Comprehensive identification of the full range of bladder cancer susceptibility variants will provide 
a basis to further our understanding of the underlying biologic mechanisms and to explore the complex 
interplay of genes and environmental and occupational exposures (38) that contribute to bladder cancer 
risk. 
 
Materials and Methods 
Study participants 
The samples and studies used are listed in Supplementary Material, Table S1. Cases and controls were non-
Hispanic Caucasians of European ancestry. Cases were defined as histologically confirmed primary 
carcinoma of the urinary bladder including carcinoma in situ (ICD-0-2 topography codes C67.0–C67.9 or 
ICD9 codes 188.1–188.9). Each study obtained informed consent from study participants and approval from 
the corresponding Institutional Review Boards (IRB). Studies obtained institutional certification permitting 
data sharing in accordance with the NIH Policy for Sharing of Data Obtained in NIH Supported or Conducted 
Genome-Wide Association Studies (GWAS). 
Genotyping and quality control 
Genotyping of cases and controls for NCI-GWAS1 and NCI-GWAS2 has previously been described (11,19) 
(Supplementary Material, Table S1). Genome-wide single-nucleotide variants (SNV) data for the first set of 
NBCS cases and controls were generated using the Illumina HumanHapCNV370-Duo (v1) or Illumina 
HumanHapCNV370-Quad (v3) BeadChip. A total of 1819 controls and 1601 bladder cancer patients passed 
pre-imputation QC (European ancestry, sample yield ≥96%, no gender mismatch, no duplicates). A second 
series of 1034 controls and 395 patients were successfully genotyped using the Illumina 
HumanOmniExpress-12 v1.1 BeadChip. 
SNPs that had suggestive interaction with smoking (rs17621407, rs12216499, rs948798, rs846906 and 
rs1711973) (21) were genotyped with optimized TaqMan genotyping assays (ABI, Foster City, CA, USA) in 
eight additional studies from Europe and the United States (Supplementary Material, Table S1). Validation 
of imputed SNPs rs4813953 and rs62185668 and GWAS array genotyped SNPs rs61088036 and rs4907479 
was done by TaqMan genotyping of 683 randomly selected DNA NCI-GWAS study samples representing 
cases and controls, with concordance rates of 99.4, 99.2, 100 and 99.7%, respectively. For the rs6104690 
SNP at 20p12.2, comparison of the genotypes from the GWAS scan with TaqMan assays has been 
previously reported (19) and showed 100% concordance. 
Imputation 
 
IMPUTE version 2 (39) was used to infer additional genotypes in the 13q34 and 20p12.2 regions using 
genotype data for 5942 cases and 10 861 (whom we had individual-level genotype data on) from the 
combined dataset of bladder cancer NCI-GWAS1 and NCI-GWAS2 (11,19), and the 1000 Genomes Project 
Phase 3 integrated haplotypes (NCBI build 37 October 2014), which contains data for 2504 individuals from 
21 populations (40). A 1 Mb window centered on SNPs rs4907479 at 13q34 or rs6104690 at 20p12.2 was 
used for imputation with a seed of 146 and 246 GWAS-genotyped SNPs, respectively. Imputation quality 
control included an assessment of overall concordance, which indicates how well the genotyped SNPs were 
imputed across samples (we used a threshold of 0.95), the average posterior probability and the IMPUTE2-
info score of individual SNPs, which indicate how well individual SNPs were imputed across a dataset (we 
used a threshold of 0.9). This resulted in an overall genotype concordance score of 95% and a final SNP 
count of 1372 for the 13q34 region and an overall concordance of 97% with a final SNP count of 2344 for 
the 20p12.2 region. We calculated the Hardy–Weinberg equilibrium (HWE) and minor allele frequencies 
(MAF) in PLINK version 1.07 (10 August 2009), and variants with strong HWE deviations in controls (P < 
10−3) were reviewed and flagged. GTOOL soŌware was used for all file conversions between pedigree and 
genotype file format. 
Association testing on the combined NCI-GWAS1 and NCI-GWAS2 datasets that included both genotyped 
and imputed variants was performed using PLINK version 1.07 (10 August 2009) based on logistic regression 
models, considering an additive genetic effect and adjusting for age (in 5-year categories), gender, 11 study 
groups, significant eigenvectors (EV 1, 5 and 6) from the principal component analysis (PCA) as previously 
described (11,19) and smoking (ever/never). Additionally, models were adjusted for the specific SNPs to 
test for the presence of any additional independently or stronger associated SNPs. Calculation of LD metrics 
(D′ and r2) and haplotype analysis for 20p12.2 locus SNPs (rs62185668, rs6104690 and rs6108803) were 
performed using PLINK. 
Fixed-effects meta-analyses were used to determine associations for the SNPs in different sub-studies 
overall and in selected strata (tumor stage and grade) using STATA, Version 11.2. Heterogeneity in genetic 
effects across study groups was evaluated using the I2 statistic. We evaluated SNP associations by stage, 
grade and high/low risk of progression tumors (low-risk tumors were defined as Ta stage with G1/G2 grade; 
high-risk tumors were T1–T4 stages or G3/G4 grade) using the combined set of NCI-GWAS1 and NCI-
GWAS2 data. Polytomous logistic regression was used to obtain OR and 95% confidence interval (CI) for 
different tumor subtypes. Case–case P-values were calculated with tumor type as an outcome and were 
used to test for differences in effect size across subtypes. Polytomous logistic regression models for tumor 
grade and stage constraining the effect size to increase linearly across levels were also calculated and 
presented as case–case trend. Additive and multiplicative interactions were conducted using categorical 
variables (each SNP was coded as a dichotomous variable indicating the presence of any risk allele) to make 
the additive and multiplicative tests comparable as previously described (15,32). 
Estimate of recombination hotspots 
SequenceLDhot (41) that uses an approximate marginal likelihood method (42) was used to compute 
likelihood ratio (LR) statistics for a set of putative hotspots across the region of interest. We sequentially 
analyzed subsets of 100 controls of European background (by pooling 5 controls from each study). We used 
Phasev2.1 to infer the haplotypes as well as background recombination rates. The analysis was repeated 
with 5 non-overlapping sets of 100 pooled controls. 
TCGA analysis 
 
Expression (RNA-seq), genotypes (Affymetrix SNP6.0 arrays) and demographic and clinical data were 
obtained from TCGA (24) from 412 bladder cancer cases. Among the 412 cases, 391 had germline genotype 
data, 363 cases had data on overall survival and 250 cases had data on recurrence. Distributions of 
genotypes of SNPs rs2993291, rs6040291 and rs6074214, which were used as proxies for GWAS SNPs, were 
in HWE and comparable with the patterns in the 1000 Genomes populations. Total gene expression values 
for JAG1, BTBD3 and MCF2L generated by TCGA as RSEM counts were log10-transformed (first adding 1 to 
all RSEM values). The log-transformed RSEM values were tested for association with SNPs based on an 
additive genetic model adjusted for age, sex and race using generalized linear models in SPSS v.21. 
Survival analysis was performed using clinical and genotype bladder cancer TCGA data (24). Overall survival 
data defined as either months until patient death or last follow-up. Hazards ratios (HR) were estimated 
using Cox regression models with the number of risk alleles (0, 1 or 2) as the independent variable and 
overall survival as the outcome adjusting for age, gender, race and smoking status (ever/never). 
Data access 
Access to the NCI-GWAS1 and NCI-GWAS2 genotypes is available for investigators from certified scientific 
institutions after approval of a submitted Data Access Request through dbGAP identifier, phs000346.v2, at 
http://www.ncbi.nlm.nih.gov/gap. 
URLs 
CGEMS portal, http://cgems.cancer.gov/; Cancer Genomics Research Laboratory, CGR, 
http://cgf.nci.nih.gov/; GLU, http://code.google.com/p/glu-genetics/; EIGENSTRAT, 
http://genepath.med.harvard.edu/~reich/EIGENSTRAT.htm; STRUCTURE, 
http://pritch.bsd.uchicago.edu/structure.html; 1000 Genomes, http://www.1000genomes.org/; TCGA, 
http://cancergenome.nih.gov/; UCSC, https://genome.ucsc.edu/; STATA, http://www.stata.com; ; dbGAP, 
http://www.ncbi.nlm.nih.gov/gap; TCGA Research Network, http://cancergenome.nih.gov, ENCODE, 
https://genome.ucsc.edu/ENCODE/; HaploReg V.3, 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php. 
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Figure 1. 
Forest plots of meta-analyses results with bladder cancer risk for SNPs rs6104690 at 20p12.2 and 
rs4907479 at 13q34. Metaplots for SNPs rs6104690 at 20p12.2 (A) and rs4907479 at 13q34 (B). Details of 
individual studies are presented in Supplementary Material, Table S1. The New England Bladder Cancer 
Study (NEBCS) represents a single study comprised of Maine (ME) and Vermont (VT) components 
genotyped in NCI-GWAS1, and the New Hampshire (NH) component genotyped in NCI-GWAS2. Fixed-
effects meta-analysis by study was used to calculate the combined OR, 95% CI and P-trend for the variant 
allele. 
Figure 2. 
Association results and LD plot for the 13q34 region. The −log10(P-value) (left Y-axis) for NCI-GWAS1 and 
NCI-GWAS2 genotyped SNPs (blue) and imputed SNPs (gray) plotted on the genomic coordinates (X axis; 
NCBI genome build 37). The combined data for NCI-GWAS1, NCI-GWAS2, TXBCS-GWAS, IBCS-GWAS, NBCS-
GWAS and TaqMan study data for the 13q34 locus marked by SNP rs4907479, are shown in red. Right Y-axis 
presents LR of putative recombination hotspots based on 5 sets of 100 randomly selected controls from 
NCI-GWAS1 and NCI-GWAS2 and shown as connected blue lines. 
Figure 3. 
Fine-mapping association analysis of the 20p12.2 region. The results are shown for five SNPs of interest: 
validated GWAS candidate rs6104690 (19), novel finding rs6108803, previously reported rs62185668 and 
rs4813953 associated with bladder cancer (18), and rs1327235 associated with systolic blood pressure (23). 
The plots are based on the combined NCI-GWAS1 and NCI-GWAS2 dataset, which includes 5551 bladder 
cancer cases and 10 242 controls of European origin. (A) Association results for bladder cancer risk (Y-axis) 
are presented as −log10(P-value) for logistic regression models, assuming additive genetic effect and 
adjusting for age, gender, 11 study groups, significant eigenvectors, smoking (ever/never) and specified 
SNPs. SNPs of interest are marked as filled diamonds: rs6104690 (red), rs6108803 (brown), rs62185668 
(green), rs4813953 (blue) and rs1327235 (orange); corresponding proxy SNPs (r2 ≥ 0.8) are presented as 
color-matched, un-filled diamonds. (B) Pairwise LD (r2 and D′) of SNPs of interest across the 33 Kb in the 
20p12.2 region. 
  
Table 1. 
Per-allele ORs and 95% CIs for SNPs at 20p12.2 locus with significant associations with bladder cancer risk in 
the combined NCI-GWAS1 and NCI-GWAS2 dataset of 5551 bladder cancer cases and 10 242 controls 
SNPa 
Alleles, 
risk-
underlined 
RAF 
cases/controls, 
% 
OR 
(95% 
CI) 
OR (95% 
CI), 
adjusted 
for 
rs6108803 
OR (95% CI), 
adjusted for 
rs62185668 
OR (95% 
CI), 
adjusted 
for 
rs6104690 
OR (95% CI), 
adjusted for 
rs6104690, 
rs62185668, 
and rs6108803 
rs6108803(G) G/A 18.2/16.1 
1.18 
(1.10–
1.26) 
P = 
1.82E 
− 06  
– 
1.12 (1.02–
1.24) 
P = 0.02  
1.14 (1.06–
1.22)/ 
P = 6.41E − 
04  
1.12 (1.01–
1.24) 
P = 0.03  
rs62185668 
(I, G) A/C 27.1/24.5 
1.14 
(1.07–
1.20) 
P = 
1.39E 
− 05  
1.05 (0.97–
1.15) 
P = 0.25  
– 
1.09 (1.02–
1.17) 
P = 9.26E − 
03  
1.02 (0.93–
1.12) 
P = 0.70  
rs6104690 
(G) A/G 59.1/55.9 
1.11 
(1.06–
1.17) 
P = 
3.97E 
− 05  
1.07 (1.01–
1.13) 
P = 0.02  
1.07 (1.01–
1.14) 
P = 0.03  
– 
1.07 (1.01–
1.13) 
P = 0.03  
 
 
 
    aG indicates SNPs genotyped by GWAS and validated by TaqMan genotyping in a subset of samples; (I, G) 
indicates a SNP imputed with high confidence and then validated by TaqMan genotyping in a subset of 
samples. All ORs and 95% CIs were adjusted for age, gender, study groups, significant eigenvectors and 
smoking status; analysis is based on samples with genotype data for all three SNPs. 
    RAF, risk allele frequency. 
  
Table 2. 
Per-allele ORs and 95% CIs for SNPs in the 20p12.2 region (rs6104690, rs6108803 and rs62185668) in the 
combined NCI-GWAS1 and NCI-GWAS2 dataset stratified by tumor stage as non-muscle-invasive (NMIBC, 
Ta-T1) and muscle-invasive (MIBC, T2-T4) bladder cancers. 
 
SNP  Controls Cases OR 
Case–control Case–Case 
 95% CI P P 
rs6104690 
Stage at diagnosis 
 NMIBC (Ta-T1) 8403 3008 1.10 1.03 1.18 5.27E−03 Ref 
 MIBC (T2-T4)  539 1.22 1.07 1.39 3.88E−03 0.20 
rs6108803 
Stage at diagnosis 
 NMIBC (Ta-T1) 7585 3010 1.10 1.01 1.21 3.33E−02 Ref 
 MIBC (T2-T4)  539 1.36 1.15 1.60 2.62E−04 0.02 
rs62185668 
Stage at diagnosis 
 NMIBC (Ta-T1) 7966 2860 1.13 1.04 1.22 2.93E−03 Ref 
 MIBC (T2-T4)  503 1.39 1.20 1.60 1.28E−05 0.01 
 
Risk alleles are A (rs6104690), G (rs6108803) and A (rs62185668). Polytomous logistic regression was used 
to obtain OR and 95% CI for tumor subtypes adjusted for age, gender, study groups, significant 
eigenvectors and smoking status. Case–case P values were calculated with tumor type as an outcome and 
were used to test for differences in effect size between NMIBC and MIBC. 
  
 
 
Figure 1. 
 
Forest plots of meta-analyses results with bladder cancer risk for SNPs rs6104690 at 20p12.2 and 
rs4907479 at 13q34. Metaplots for SNPs rs6104690 at 20p12.2 (A) and rs4907479 at 13q34 (B). Details of 
individual studies are presented in Supplementary Material, Table S1. The New England Bladder Cancer 
Study (NEBCS) represents a single study comprised of Maine (ME) and Vermont (VT) components 
genotyped in NCI-GWAS1, and the New Hampshire (NH) component genotyped in NCI-GWAS2. Fixed-
effects meta-analysis by study was used to calculate the combined OR, 95% CI and P-trend for the variant 
allele. 
  
 
 
 
Figure 2. 
Association results and LD plot for the 13q34 region. The −log10(P-value) (left Y-axis) for NCI-GWAS1 and 
NCI-GWAS2 genotyped SNPs (blue) and imputed SNPs (gray) plotted on the genomic coordinates (X axis; 
NCBI genome build 37). The combined data for NCI-GWAS1, NCI-GWAS2, TXBCS-GWAS, IBCS-GWAS, NBCS-
GWAS and TaqMan study data for the 13q34 locus marked by SNP rs4907479, are shown in red. Right Y-axis 
presents LR of putative recombination hotspots based on 5 sets of 100 randomly selected controls from 
NCI-GWAS1 and NCI-GWAS2 and shown as connected blue lines. 
  
  
 
Figure 3. 
Fine-mapping association analysis of the 20p12.2 region. The results are shown for five SNPs of interest: 
validated GWAS candidate rs6104690 (19), novel finding rs6108803, previously reported rs62185668 and 
rs4813953 associated with bladder cancer (18), and rs1327235 associated with systolic blood pressure (23). 
The plots are based on the combined NCI-GWAS1 and NCI-GWAS2 dataset, which includes 5551 bladder 
cancer cases and 10 242 controls of European origin. (A) Association results for bladder cancer risk (Y-axis) 
are presented as −log10(P-value) for logistic regression models, assuming additive genetic effect and 
adjusting for age, gender, 11 study groups, significant eigenvectors, smoking (ever/never) and specified 
SNPs. SNPs of interest are marked as filled diamonds: rs6104690 (red), rs6108803 (brown), rs62185668 
(green), rs4813953 (blue) and rs1327235 (orange); corresponding proxy SNPs (r2 ≥ 0.8) are presented as 
color-matched, un-filled diamonds. (B) Pairwise LD (r2 and D′) of SNPs of interest across the 33 Kb in the 
20p12.2 region. 
